Please login to the form below

Not currently logged in
Email:
Password:

oral semaglutide

This page shows the latest oral semaglutide news and features for those working in and with pharma, biotech and healthcare.

Novo’s oral diabetes drug hits the mark again

Novo’s oral diabetes drug hits the mark again

The 26-week phase IIIa trial, also known as PIONEER 5, investigated oral semaglutide in 324 patients with type 2 diabetes and who have a kidney-impairment, a serious diabetes complication. ... in people with type 2 diabetes and moderate renal impairment,

Latest news

More from news
Approximately 3 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Oral biologics delivery still elusive Oral biologics delivery still elusive

    Novo Nordisk is also working with another specialist on oral delivery for protein drugs - Emisphere Technologies - that has applied its Eligen technology to develop an oral version of semaglutide, a ... rarely as once a quarter for example, which makes

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics